Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Baxter Cardiovascular Business To Boost R&D Spending After Spin-Off

This article was originally published in The Gray Sheet

Executive Summary

The soon-to-be independent Baxter Cardiovascular Group's R&D spending is expected to increase by 50% over the current coporate rate of 6%.

You may also be interested in...



Edwards' $45 Mil. Sale Of CRI Marks End Of Post-Baxter Restructuring

Edwards Lifesciences has completed the divestment phase of its ongoing reorganization strategy with the sale of its $120 mil. perfusion services business, Cardiovascular Resources, Inc. (CRI), to Fresenius Medical Care for $45 mil.

Edwards' $45 Mil. Sale Of CRI Marks End Of Post-Baxter Restructuring

Edwards Lifesciences has completed the divestment phase of its ongoing reorganization strategy with the sale of its $120 mil. perfusion services business, Cardiovascular Resources, Inc. (CRI), to Fresenius Medical Care for $45 mil.

Baxter To Sell CVG's Products In Fringe International Markets After Spin-off

Baxter Healthcare will continue to distribute products produced by its Cardiovascular Group spin-off in several countries outside of the U.S., including Argentina, Australia, Greece, Ireland, New Zealand and certain Scandinavian countries, after CVG Controlled, Inc. becomes a separate entity in the first half of 2000.

Related Content

UsernamePublicRestriction

Register

MT012046

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel